Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial.
about
Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.Infectious diseases causing autonomic dysfunction.4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.Combined parasitological and molecular-based diagnostic tools improve the detection of Trypanosoma cruzi in single peripheral blood samples from patients with Chagas disease.Phenotypic screening approaches for Chagas disease drug discovery.
P2860
Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Chronic Chagas cardiomyopathy: ...... ypanosomiasis (BENEFIT) trial.
@en
Chronic Chagas cardiomyopathy: ...... r Interrupting Trypanosomiasis
@nl
type
label
Chronic Chagas cardiomyopathy: ...... ypanosomiasis (BENEFIT) trial.
@en
Chronic Chagas cardiomyopathy: ...... r Interrupting Trypanosomiasis
@nl
prefLabel
Chronic Chagas cardiomyopathy: ...... ypanosomiasis (BENEFIT) trial.
@en
Chronic Chagas cardiomyopathy: ...... r Interrupting Trypanosomiasis
@nl
P2093
P2860
P356
P1476
Chronic Chagas cardiomyopathy: ...... ypanosomiasis (BENEFIT) trial.
@en
P2093
Anis Rassi
José Antonio Marin
P2860
P356
10.1590/0074-02760160334
P577
2017-02-16T00:00:00Z